You are currently browsing the archives for the EMCDDA category.
25/05/2010 by admin.
Twenty four new psychoactive drugs were reported to the official European monitoring centre during 2009, the largest number ever reported in a single year.
All the new drugs were synthetic compounds, and included 9 cannabinoid (cannabis) like substances.
The growth in synthesised drugs, side-stepping current legal restrictions to enable fast market and internet sales of “legal highs” seems to have been the growth trend of 2009 with a reduction in MDMA in tablets sold as E’s and substitution with Piperazine mCPP like substances.
As the UK moves to legislate to cover these developments, the market will move to traditional criminal production and supply chains associated with established drug groups.
There is still no test available for any of these new drugs, making screening and detection difficult.
Posted in Mephadrone use, pre-employment Drug Testing, Mephedrone, Mephedrone drug, Mephedrone ban, MCAT, Methadrone, Drug Classifiaction, EMCDDA, Mephadrone, Meow meow drug, Mephadrone drug, ecstasy | 1 Comment »
25/11/2008 by admin.
Below is an extract from EMCDDA annual report published 6th November 2008
Nearly a quarter of all Europeans, or around 71 million (15–64 years), have tried cannabis in their lifetime, and around 7 % (23 million) have used it in the last year — making it still Europe’s most commonly consumed illicit drug. But, in some important markets, there are now ’stronger signals’ of the drug’s waning popularity, reinforcing the analysis presented in last year’s Annual report
Click here to read more on rates of Cannabis use from EMCDDA
Posted in EMCDDA, Cannabis | No Comments »
25/11/2008 by admin.
Warning signs over Europe’s biggest drug problem
Opioids are still at the heart of Europe’s drug phenomenon. And signs of change in our heroin and synthetic opioid problem mean that countries need to be vigilant and prepared to respond. These were among the key points stressed by the EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) as it launched its annual report: the state of the drugs problem in Europe on 6 November in Brussels.
Estimates show that there are between 1.3 and 1.7 million problem opioid users in the EU and Norway, with heroin responsible for Europe’s largest drug-related health and social costs. New data published in the report call into question previous EMCDDA assessments of a slowly improving heroin situation and point to a ’stable, but no longer diminishing problem’. Record opium production in Afghanistan in 2007 has also heightened the agency’s worries over a potential knock-on effect on Europe’s heroin problem
Click here to read the full report from EMCDDA on Opiods
Stimulant drugs — such as amphetamines, ecstasy and cocaine — are the second most commonly consumed drug type in Europe today, after cannabis. But within this group, data reveal a very mixed picture in terms of prevalence, trends and market developments.
Click here to read more on stimulant drugs from EMCDDA
Posted in Stimulant Drugs, EMCDDA, Heroin | No Comments »